gadolinium-chelate

Phase 2Small molecule

MM.D. Anderson Cancer Center

gadolinium-chelate is one of 128 small molecule programs targeting Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Brain CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

MetastasisPreclinical

Active, not recruiting

Brain CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Tykerb

GSK

Preclinical

80 3

Prolia

Amgen

Preclinical

14 4

gadolinium-chelate

MM.D. Anderson Cancer Center

Phase 2

1 5

Lexiscan

Astellas

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Brain Cancer

NCT06319027

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer

Unknown status·RRoyal Marsden NHS Foundation Trust·N/A·NCT00602316·20 enrolled

Metastasis1 trial

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Completed·MM.D. Anderson Cancer Center·N/A·NCT04870645·15 enrolled

Prostate Cancer1 trial

Dutasteride in Treating Patients With Prostate Cancer

Unknown status·UUniversity College London Hospitals·Phase 2·NCT01193855·42 enrolled

Brain Cancer1 trial

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT06319027·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for gadolinium-chelate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gadolinium-chelate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gadolinium-chelate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

gadolinium-chelate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Breast Cancer1 trial

Metastasis1 trial

Prostate Cancer1 trial

Brain Cancer1 trial

References

Drug Info

Quick Facts

Related News